Impact of comorbid polycystic ovarian syndrome and gestational diabetes mellitus on pregnancy outcomes: a retrospective cohort study

Varun Manoharan1,2* and Vincent W. Wong1,2

Abstract

Background: Gestational diabetes mellitus (GDM) and polycystic ovarian syndrome (PCOS) have been associated with adverse maternal and neonatal outcomes, but the evidence on the impact of coexistent PCOS and GDM is rather limited and inconclusive. We investigated the impact of comorbid PCOS on pregnancy outcomes among women with GDM.

Methods: This retrospective cohort study included women diagnosed with GDM on 75 g oral glucose tolerance test on routine antenatal screening tests at Liverpool Hospital between February 2015 and January 2019. Women were then grouped into those with and without PCOS based on the Rotterdam criteria. The demographic details, clinical data and pregnancy outcomes were compared between the two groups.

Results: Among the 1545 women with GDM included in the study, there were 326 women with PCOS. Women with GDM and PCOS (GDM+PCOS+) were younger (29.5 years vs 31.5 years, \( p < 0.001 \)), more likely to be primigravidae (31.9% vs 20%, \( p < 0.001 \)), as well as of Caucasian descent (37.4% vs 21.7%, \( p < 0.001 \)). PCOS was an independent risk factor for the development of preeclampsia on regression analysis (OR 2.06, \( p = 0.021 \)). Women with PCOS and GDM had a higher body mass index (31.5 kg/m\(^2\) vs 27.7 kg/m\(^2\), \( p < 0.001 \)), significant gestational weight gain (12.6 kg vs 11.5 kg, \( p = 0.016 \)), and more frequent use of pharmacotherapies to manage their GDM (57.7% vs 45.2%, \( p < 0.001 \)). There was no statistically significant difference in the rates of adverse neonatal outcomes in both the groups.

Conclusion: Among women with GDM, PCOS was an independent risk factor for the development of preeclampsia and significant gestational weight gain, warranting vigilant monitoring of blood pressure, blood glucose levels and body weight, and implementing timely interventions to improve obstetric and neonatal outcomes.

Keywords: Gestational diabetes mellitus, Polycystic ovarian syndrome, Pregnancy, Outcomes, Complications
Background
Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder that affects women of reproductive age with a prevalence of 12–21% [1], and it has a profound impact on the psychological, reproductive and metabolic health of women [2]. The Rotterdam criteria, the most widely used criteria for the diagnosis of PCOS, encompasses any two of the following three criteria: ovulatory dysfunction, sonographic evidence of polycystic ovarian morphology, and biochemical evidence or clinical features associated with hyperandrogenism [3]. Women with PCOS have a higher risk of developing type II diabetes (T2DM) [4–6]. Some [7, 8], but not all [9–11], studies suggest that PCOS increases the risk of developing GDM. Insulin resistance is a common metabolic aberration in GDM [12] and PCOS [13, 14]. Both GDM [15, 16] and PCOS [17, 18] have been associated with adverse maternal and neonatal outcomes. The evidence on the maternal, pregnancy and neonatal outcomes among women with coexistent PCOS and GDM (GDM+PCOS+) is rather limited and inconclusive [19–22].

The study aims to retrospectively evaluate the impact of comorbid PCOS on pregnancy outcomes among women with GDM. The study is explorative and aims to contribute to the existing literature on vigilant monitoring of blood glucose levels and implementing timely interventions among pregnant women with PCOS and GDM in order to improve obstetric and neonatal outcomes.

Methods
This retrospective cohort study was performed on women diagnosed with GDM on routine antenatal screening with the 75 g oral glucose tolerance test (OGTT) at Liverpool Hospital between February 2015 and January 2019. We defined GDM as fasting plasma glucose level greater than 5.1 mmol/L, one hour plasma glucose level greater than 10.0 mmol/L and two hour plasma glucose level greater than 8.5 mmol/L as per the consensus guidelines released by the Australasian Diabetes in Pregnancy Society [23]. All women completed a standardised, self-report questionnaire during their first antenatal visit, which included demographic information, medical history, obstetric history and psychosocial history (Supplement 1). The medical history included a question about previous diagnoses of PCOS. Women who reported to have PCOS were confirmed about their diagnosis based on the Rotterdam criteria. Demographic, clinical and follow-up data were gathered through the South Western Sydney Local Health District (SWSLHD) electronic medical record system. Clinical variables of interest included obstetric history, anthropometric data, glycaemic parameters in the index OGTT, antenatal complications such as the incidence of preeclampsia, and neonatal complications including macrosomia, neonatal hypoglycaemia, and admission of the neonate to the neonatal intensive care unit.

The GDM database project was approved by the SWSLHD Human Research Ethics Committee. Patient consent was waived in accordance to the ethics proposal approved by the SWSLHD Human Research Ethics Committee on the basis that the project was deemed to be of low and negligible risk, and that the retrospective consent of 1545 women enrolled in this study would have placed undue burden on those involved in this research.

Statistical analyses were performed using IBM SPSS Statistics 21. Absolute numbers and percentages were used to describe the patient population. Normal distribution of continuous variables was tested using Kolmogorov-Smirnov and Shapiro-Wilk tests. Quantitative variables that were normally distributed are expressed as mean and standard deviation. Where the quantitative variables were not normally distributed, the values are presented as median and range. Independent two sample t-test was used to analyse continuous variables, and chi-square test was used to examine associations between categorical variables. Logistic regression testing was used to adjust for confounding variables. A p < 0.05 was considered statistically significant.

Results
Among the 1545 women with GDM included in the study, there were 326 (21.1%) women with PCOS. Women with GDM and PCOS (GDM+PCOS+) were younger (29.5 years vs 31.5 years, p < 0.001) and more likely to be primigravidae (31.9% vs 20%, p < 0.001), current smokers (11.1% vs 7.2%, p < 0.001) as well as of Caucasian descent (37.6% vs 21.8%, p < 0.001). Anthropometrically, GDM+PCOS+ women recorded a higher body mass index (31.5 kg/m² vs 27.7 kg/m², p < 0.001) and a statistically significant gestational weight gain (12.6 kg vs 11.5 kg, p = 0.016).

In our study, GDM+PCOS+ women had a lower incidence of previous GDM (18.9% vs 36.3%, p < 0.001) with nulliparous removed from this analysis. There was a significantly higher usage of metformin (20.5% vs 12.4%, p < 0.005) and insulin (57.1% vs 44.1%, p < 0.001) in these women with a small proportion of women requiring a combination of metformin and insulin (5.4% vs 4.3%). Although GDM+PCOS+ women had a higher mean fasting blood glucose level (BGL) on OGTT (5.4 mmol/L vs 5.1 mmol/L, p = 0.006), there were no significant differences in the other glycaemic parameters, including the mean BGL at 1 h and 2 h, and the HbA1c at diagnosis of GDM (Table 1).

In terms of pregnancy outcomes, there was a significantly higher incidence of preeclampsia among
GDM+PCOS+ women (Table 2) compared to those without PCOS. The association between plasma glucose level one hour after 75 g OGTT and the likelihood of pre-eclampsia was almost significant among GDM+PCOS+ women (10.4 mmol/L vs 9.4 mmol/L, p = 0.051), and not among GDM+PCOS0 women (9.9 mmol/L vs 9.8 mmol/L, p = 0.910). On subgroup analysis, there were no significant associations between the other glycaemic indices and the likelihood of developing preeclampsia in our study population. The proportion of neonates born to GDM+PCOS+ women with an APGAR score less than 7 at one minute was significantly higher (13.5% vs 8.9%, p = 0.021), whilst the incidence of all the other adverse neonatal outcomes, such as APGAR score less than 7 at five minutes, congenital abnormalities, neonatal hypoglycaemia, prematurity, macrosomia, admission to neonatal intensive care unit and neonatal death did not retain statistical significance (Table 2).

**Discussion**

A significantly higher proportion primigravidae with GDM had comorbid PCOS (Table 1) and PCOS has been associated with dysglycaemic states such as GDM and T2DM, but the impact of co-existent GDM in women with PCOS on maternal and neonatal outcomes is rather uncertain [19–21]. Our main finding is that GDM+PCOS+ women had a higher incidence of preeclampsia (Table 2). Interestingly, the rate of pre-existing hypertension was not different between those

### Table 1 Patient characteristics, anthropometric profile and glycaemic profile

|                          | GDM+PCOS+ | GDM+PCOS0 | p-value |
|--------------------------|-----------|-----------|---------|
| **N**                    | 326       | 1215      |         |
| **Mean age (years)**     | 29.5 (±4.4) | 31.5 (±5.3) | <0.001 |
| **Ethnicity**            |           |           | <0.001 |
| Caucasian                | 124 (37.8) | 266 (21.8) |         |
| Non Caucasian            | 204 (62.2) | 951 (78.2) |         |
| Africans                 | 6 (1.8)    | 40 (3.2)   |         |
| Southeast Asians         | 30 (9.2)   | 257 (21.2) |         |
| South Asians             | 42 (12.8)  | 226 (18.6) |         |
| Pacific Islanders        | 16 (4.8)   | 88 (7.3)   |         |
| Middle-East              | 96 (29.4)  | 312 (25.7) |         |
| South Americans          | 4 (1.2)    | 15 (1.2)   |         |
| Indigenous               | 6 (1.8)    | 10 (0.8)   |         |
| Other                    | 4 (1.2)    | 3 (0.2)    |         |
| **Gravidity**            |           |           | <0.001 |
| Primigravidity           | 104 (31.9) | 244 (20)   |         |
| Multigravidity           | 222 (68.1) | 973 (80)   |         |
| <5 pregnancies           | 180 (55.2) | 740 (60.1) |         |
| ≥5 pregnancies           | 42 (12.9)  | 233 (19.1) |         |
| **Smoking status**       |           |           | 0.020   |
| Smokers                  | 36 (11.1)  | 87 (7.2)   |         |
| Non-smokers              | 288 (88.9)| 1129 (92.8)|         |
| **Family History of diabetes** |         |           | 0.950   |
| Yes                      | 150 (46.6) | 562 (46.8)|         |
| No                       | 172 (53.4) | 639 (53.2)|         |
| **Past history of GDM**  |           |           | <0.001  |
| Yes                      | 32 (18.9)  | 305 (36.3)|         |
| No                       | 138 (81.1) | 536 (63.7)|         |
| **Mean Body Mass Index (kg/m^2)** | 31.5 (±6.7) | 27.7 (±9.4) | <0.001  |
| **Body Habitus**         |           |           | <0.001  |
| Non-obese                | 200 (62.5) | 836 (68.5)|         |
| Obesity (BMI>30)         | 120 (37.5) | 384 (31.5)|         |
| **Mean gestational weight gain (kg)** | 12.6 (±7.7) | 11.5 (±7.4) | 0.016   |
| **Previous insulin use** |           |           | 0.357   |
| Yes                      | 30 (9.2)   | 144 (11.8)|         |
| No                       | 296 (90.8) | 1072 (88.2)|        |
| **Use of Metformin during current pregnancy** |         |           | 0.005   |
| Yes                      | 64 (20.5)  | 151 (12.4)|         |
| No                       | 248 (79.5) | 1064 (87.6)|        |
| **Insulin used during current pregnancy** |         |           | <0.001  |
| Yes                      | 178 (57.1) | 536 (44.1)|         |
| No                       | 134 (42.9) | 679 (55.9)|         |

|                          | GDM+PCOS+ | GDM+PCOS0 | p-value |
|--------------------------|-----------|-----------|---------|
| **Management during current pregnancy** |           |           | <0.001  |
| Nil medications          | 132 (42.3)| 666 (54.8)|         |
| Metformin only            | 47 (15.1) | 98 (8.1)  |         |
| Insulin only              | 116 (37.2)| 399 (32.8)|         |
| Combination               | 17 (5.4)  | 52 (4.3)  |         |
| **Mean dose of prandial insulin at the end of pregnancy (units)** | 37.7 (±59.5) | 35.4 (±39.2) | 0.425 |
| **Mean dose of basal insulin at the end of pregnancy (units)** | 18.5 (±23.9) | 17.0 (±17.3) | 0.529 |
| **Mean fasting BGLb on OGTT (mmol/L)** | 5.4 (±3.6) | 5.1 (±0.7) | 0.006 |
| **Mean 1 hour BGLb on OGTT (mmol/L)** | 9.7 (±1.7) | 9.9 (±1.8) | 0.225 |
| **Mean 2 hour BGLb on OGTT (mmol/L)** | 7.7 (±1.7) | 7.8 (±2.2) | 0.469 |
| **Mean HbA1c at diagnosis** | 5.2 (±0.4) | 5.2 (±0.4) | 0.539 |

*aNulliparous women were not included in this analysis; bBlood glucose level

---

Manoharan and Wong BMC Pregnancy and Childbirth (2020) 20:484
with or without PCOS, but all the women with pre-existing hypertension in the GDM+PCOS group developed preeclampsia. Women with GDM who developed preeclampsia recorded a significantly higher BMI (32.5 kg/m² vs 28.3 kg/m², \(p = 0.001\)). Obesity has been associated with a higher risk of developing preeclampsia [22, 24–26], and BMI could confound the association between PCOS and preeclampsia. However, PCOS remained an independent risk factor for the development of preeclampsia on regression analysis (OR 2.06, \(p = 0.021\)), when adjusted for age, BMI, parity, family history of diabetes mellitus, ethnicity and smoking status. This finding is in keeping with a large meta-analysis conducted by Boomsa et al. [27], in which GDM+PCOS women had more than a five-fold risk of developing preeclampsia; while Foroozanfard et al. [19] found that these women had a 2.8 fold risk of developing preeclampsia. However, Mikola and colleagues [7] demonstrated that PCOS increased the risk of developing GDM and not preeclampsia.

A prospective, randomised, multicenter study showed a statistically significant association between first trimester HbA1c and the incidence of preeclampsia [28]. In our study, women who developed preeclampsia had a significantly higher HbA1c on diagnosis of GDM (5.4% vs 5.2%, \(p = 0.037\)). Surprisingly, this correlation only retained statistical significance on subgroup analysis among GDM+PCOS women and not in GDM+PCOS women (Table 3). Similarly, the literature also reports a significant correlation between fasting blood glucose level and the likelihood of developing preeclampsia [15], but interestingly, this was also only statistically significant among GDM+PCOS women in our study. These findings not only reflect the complex metabolic aberrations in PCOS, but they also highlight the scarcity of research on pregnancy outcomes in women with GDM with comorbid PCOS.

Interestingly, among women with GDM and PCOS, we found a statistically significant association between plasma glucose one hour after 75 g OGTT and the likelihood of preeclampsia was almost significant only among GDM+PCOS women (10.4 mmol/L vs 9.4 mmol/L, \(p = 0.051\)), and this is in keeping with Joffe et al. [29] who found a significant association between plasma glucose one hour after a 50 g glucose challenge and the likelihood of preeclampsia. On subgroup analysis, there were no significant associations between the other glycaemic indices and the likelihood of developing preeclampsia in our study population (Table 3). These findings highlight the importance of monitoring women with GDM and PCOS for preeclampsia to optimise pregnancy outcomes.

We also found significant differences in the anthropometric parameters between women with and without PCOS. Foroozanfard et al. [19] found no statistically significant difference in the BMI of GDM+PCOS women and GDM+PCOS women included in their study, but our analysis showed that obese women with GDM had a higher chance of having comorbid PCOS (OR 2.973, \(p < 0.001\)) when adjusted for age, parity, ethnicity and past history of GDM, all of which were statistically significant co-variables. Women with GDM and PCOS not only had a higher pre-pregnancy BMI, they also put on more weight during pregnancy (Table 2), and these findings are congruent with the literature [30, 31]. Catalano and Shankar [31] reported long-term implications of gestational weight gain and postpartum weight retention, including an increased risk of venous thromboembolism, depression, difficulty with breast feeding and future cardiovascular risk. Due to the higher BMI at baseline and greater gestational weight gain during pregnancy, there is a greater need to assist these women in terms of weight management in the postpartum period.

We found that GDM+PCOS women had a significantly higher fasting blood glucose level on OGTT, which is in keeping with that of Radon et al. [32] and a meta-analysis conducted by Yu et al. [33] These studies had also shown that maternal obesity was related to fasting glucose levels on OGTT, and we had similar findings on one way ANOVA testing (F(289,1226) = 1.384, \(p < 0.001\)). Interestingly, on subgroup analysis, we found a statistically significant correlation between BMI of GDM+PCOS women and fasting blood glucose level (F(91,231) = 1.285, \(p = 0.049\)), one hour plasma glucose level (F(84,205) = 5.048, \(p < 0.001\)) and two hour plasma glucose level (F(88,223) = 4.120, \(p < 0.001\)). Among GDM women without PCOS, maternal BMI was only associated with a higher fasting blood glucose level (F(276, 915) = 2.296, \(p < 0.001\)). These findings highlight the additive impact of PCOS on glucose metabolism among women with GDM. Evidencing the importance of monitoring the glycaemic parameters and anthropometric parameters during pregnancy.

There was a significant difference in the management of GDM in women with PCOS, with a higher proportion of them requiring pharmacological intervention (Table 2). A small proportion of GDM+PCOS women in our study required a combination of metformin and insulin (5.4% vs 4.3%), but this is significantly lower compared to 10–44% requirement for supplemental insulin reported by Balani et al. [34] and Rowan et al. [35] On subgroup analysis, GDM+PCOS women who were not on metformin had a significantly higher rate of requiring insulin (OR 37.3, \(p < 0.001\)) and had higher total insulin requirements at the end of pregnancy (66.9 units vs 26.5 units, \(p = 0.044\)). Interestingly, on subgroup analysis, the use of metformin among GDM+PCOS women was only associated with lower total insulin requirements (11.3 units vs 75.1 units, \(p = 0.043\)) among women who were not obese. Our
findings are reflective of the complex overlap of metabolic aberrations such as insulin resistance and weight-dependent, altered insulin metabolism associated with obesity and PCOS, which compound the risk of developing GDM. Furthermore, our results highlight the therapeutic role of metformin in the management of insulin resistance caused by PCOS and GDM, but we lack data on whether metformin was commenced preconception. Women who were on metformin pre-conception usually stopped the medication at the end of first trimester, and we are unclear whether the use of metformin in early pregnancy had an impact on the women’s metabolic profile and pregnancy outcomes in the latter part of pregnancy.

The association between PCOS and Caesarean section has been established in the literature [11, 27], but the evidence regarding its incidence in women with PCOS and GDM is rather limited. Foroozanfard et al. [19] reported no significant difference in the incidence of Caesarean section between GDM+PCOS+ and GDM+PCOS0 women. However, in our study, even though there was no significant difference in the mode of delivery between the two groups, we found that a higher proportion of women with coexistent GDM and PCOS who had vaginal deliveries required induction of labour and a significantly larger proportion of GDM+PCOS+ underwent Caesarean section required it as an emergency procedure (Table 2). These findings highlight the importance of vigilantly monitoring these women, especially in the third trimester to plan their delivery and their postpartum care.

The literature also reports a higher incidence of adverse neonatal outcomes among GDM+PCOS+ women [7, 8]. Neonates born to women with GDM and PCOS

Table 2 Pregnancy and Neonatal outcomes

|                  | GDM+PCOS+ | GDM+PCOS0 | p-value |
|------------------|-----------|-----------|---------|
| Preeclampsia     |           |           | 0.010   |
| Yes              | 22 (6.7)  | 35 (2.9)  |         |
| No               | 304 (93.3)| 1180 (97.1)|        |
| Hypertension in pregnancy | | | 0.767 |
| Yes              | 22 (6.7)  | 74 (6.1)  |         |
| No               | 304 (93.3)| 1144 (93.9)|        |
| Mode of delivery |           |           | 0.732   |
| Vaginal delivery | 218 (66.9)| 807 (67.8)|         |
| Caesarean section| 108 (33.1)| 382 (32.2)|         |
| Vaginal delivery |           |           | 0.025   |
| Spontaneous onset of labour | 102 (46.8)| 446 (55.2)|         |
| Induction of labour | 116 (53.2)| 361 (44.8)|         |
| Caesarean Section |           |           | 0.004   |
| Emergency C-section | 50 (46.3)| 120 (31.4)|         |
| Elective C-section | 58 (53.7)| 262 (68.6)|         |
| Mean week of Delivery | 38.47 (30-41)| 38.24 (10-42)| 0.739 |
| Prematuritya    |           |           | 0.753   |
| Yes             | 32 (9.8)  | 90 (7.5)  |         |
| No              | 294 (90.2)| 1116 (92.5)|        |
| APGAR<7 at 1 mins (%) | 13.5 | 8.9 | 0.021 |
| APGAR<7 at 5 mins (%) | 1.8 | 2.7 | 0.547 |
| Mean neonatal birth weight | 3309.5 (1342-4545) | 3308.5 (1000-5420) | 0.982 |
| Macrosomiab     |           |           | 0.193   |
| Yes             | 36 (11)   | 103 (8.6) |         |
| No              | 290 (89)  | 1092 (91.4)|        |
| Admission to NICU |            |           | 0.556   |
| Yes             | 42 (12.9) | 174 (14.6)|         |
| No              | 284 (87.1)| 1017 (85.4)|        |
| Neonatal hypoglycaemiac | | | 0.406 |
| Yes             | 40 (12.3) | 121 (10.2)|         |
| No              | 286 (87.7)| 1071 (89.8)|        |
| Admission to NICU with hypoglycaemia | | | 0.102 |
| Yes             | 28 (8.6)  | 72 (6)    |         |
| No              | 298 (91.4)| 1120 (94) |         |
| Neonatal death  |           |           | 0.248   |
| Yes             | 2 (0.1)   | 17 (0.1)  |         |
| No              | 324 (99.1)| 1186 (99.9)|        |

Table 2 Pregnancy and Neonatal outcomes (Continued)

|                  | GDM+PCOS+ | GDM+PCOS0 | p-value |
|------------------|-----------|-----------|---------|
| Congenital abnormality | | | 0.314 |
| Yes             | 8 (2.5)   | 33 (2.8)  |         |
| Ankyloglossia   | 4 (1.3)   | 1 (0.2)   |         |
| Cardiovascular  | 0 (0)     | 5 (0.4)   |         |
| Gastrointestinal| 0 (0)     | 1 (0.2)   |         |
| Limb abnormalities| 2 (0.6) | 14 (1.1)  |         |
| Neurological    | 0 (0)     | 5 (0.4)   |         |
| Genitourinary   | 2 (0.6)   | 4 (0.3)   |         |
| Other           | 0 (0)     | 3 (0.2)   |         |
| No              | 318 (97.5)| 1162 (97.2)|        |

aPrematurity is defined as delivery before 37 weeks of gestation; bMacrosomia is defined as birthweight above 4,000g; cNeonatal hypoglycaemia is defined as blood glucose level below 2.5mmol/L within the first 24 hours of birth
had a higher incidence of hypoglycaemia (12.3% vs 10.2%, \(p = 0.406\)) and admission to NICU with hypoglycaemia (8.6% vs 6%, \(p = 0.102\)). Similarly, there was a higher incidence of macrosomia among neonates born to GDM\(^*\)PCOS\(^+\) women (11% vs 8.6%, \(p = 0.193\)). However, these associations were not statistically significant in our study because our study was not powered for these outcomes.

Interestingly, there was a higher rate of smoking amongst women with PCOS, despite the known association between PCOS and cardiovascular risk factors [31]. This may need to be addressed especially by the primary care physician postpartum to minimise the adverse long-term impact on their cardiovascular health.

Strengths of our study include the recruitment of a large, multicultural and unselected community cohort retrospectively with data collection in real time during follow-ups in the antenatal clinic, which enhances the external validity of the study. Furthermore, we adjusted for statistically significant confounders noted on univariate analysis and confounders reported in the literature to optimise the validity of the data.

We note several limitations in our study. The diagnosis of PCOS was based on a screening question at the time of antenatal booking, and those who self-reported to have PCOS were confirmed about the diagnosis based on the Rotterdam criteria. There is inherent potential for misidentification as there would be women with this condition who were not aware of the diagnosis of PCOS. Furthermore, our study only involved women with GDM; hence we were unable to comment on the impact of PCOS on women who did not develop GDM. The lack of follow-up data relating to post-partum OGTT deterred us from analysing the impact of coexistent GDM and PCOS on the maternal risk of developing T2DM. Owing to the lack of data on the management of PCOS prior to the index pregnancy, especially the duration of metformin therapy, we were unable to evaluate the therapeutic implications of metformin use in PCOS in relation to maternal and foetal outcomes. We also lack data on the use of aspirin in our cohort, which deterred us from analysing the impact of aspirin use on the incidence of pre-eclampsia. Our study was not powered to detect a significant difference among adverse neonatal outcomes associated with GDM, which have been widely reported in the literature.

**Conclusion**

In conclusion, in our study that only addresses women with GDM, we found that there were significant differences in demographic, anthropometric and glycaemic parameters in the presence of comorbid PCOS. The coexistence of PCOS among women with GDM was associated with a higher pre-pregnancy BMI and significant gestational weight gain, and comorbid PCOS was an independent risk factor on regression analysis for the development of preeclampsia among women with GDM, all of which have been shown to have long term implications on the health of the mother and the infant. Our findings highlight the importance of regular antenatal follow-up of women with GDM and PCOS, vigilant monitoring of blood pressure and glycaemic control, and better control of gestational weight gain in order to optimise obstetric and neonatal health outcomes.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12884-020-03175-5.

**Additional file 1.** Supplementary file 1. Figure 1 A snapshot of the online antenatal booking sheet. A standardised, self-report questionnaire completed by all women during their first antenatal visit, which includes demographic information, medical history, obstetric history and psychosocial history. The medical history included a question about previous diagnoses of PCOS.

**Abbreviations**

BMI: Body Mass Index; GDM: Gestational diabetes mellitus; PCOS: Polycystic ovarian syndrome; GDM\(^*\)PCOS\(^+\): Women with gestational diabetes mellitus and polycystic ovarian syndrome; GDM\(^*\)PCOS\(^0\): Women with gestational diabetes mellitus and no polycystic ovarian syndrome; OGTT: Oral glucose tolerance test; SWSLHD: South Western Sydney Local Health District; T2DM: Type II diabetes mellitus

**Acknowledgements**

All parties who have contributed to this research article have been acknowledged.

**Authors’ contributions**

Both authors involved in the study, data analysis and writing of this paper have been listed. The author(s) read and approved the final manuscript.

### Table 3 Glycaemic parameters in women who developed preeclampsia

|                        | GDM\(^*\)PCOS\(^+\) | GDM\(^*\)PCOS\(^0\) |
|------------------------|---------------------|---------------------|
| **HbA1c at diagnosis (%)** | 5.2 (±0.5)         | 5.2 (±0.4)         | 0.639  | 5.5 (±0.6) | 5.2 (±0.4)  | 0.045  |
| **Mean fasting BGL\(^b\) on OGTT (mmol/L)** | 5.2 (±0.4)         | 5.4 (±3.7)         | 0.740  | 5.5 (±0.9) | 5.1 (±0.7)  | 0.027  |
| **Mean 1 hour BGL\(^b\) on OGTT (mmol/L)** | 10.4 (±1.6)        | 9.4 (±1.7)         | 0.051  | 9.9 (±2.1) | 9.8 (±1.7)  | 0.910  |
| **Mean 2 hour BGL\(^b\) on OGTT (mmol/L)** | 7.7 (±1.5)         | 7.7 (±1.7)         | 0.991  | 7.6 (±1.9) | 7.8 (±2.1)  | 0.566  |

\(^a\)Preeclampsia; \(^b\)Blood glucose level
References

1. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed using under contrasting diagnostic criteria. Hum Reprod. 2010;25:444–51.

2. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.

3. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.

4. Gambineri A, Patton L, Attie P, Pagotto U, Pizzi C, Manzoli L, et al. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes. 2012;61(12):2369–74.

5. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141–6.

6. Legro RS, Gnatul CS, Kunselman AR, Dunafi A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005;90:3236–42.

7. Micol A, Hilesmaa V, Halttunen M, Suhonen L, Tiltinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod. 2001;16(2):226–9.

8. Rees DA, Jenkins-Jones S, Morgan CL. Contemporary reproductive outcomes for patients with polycystic ovary syndrome: a retrospective observational study. J Clin Endocrinol Metab. 2016;101:1664–72.

9. Mustanemi S, Valiairasni M, Eriksson JG, Gissler M, Laiouho H, Liius H, et al. Polycystic ovary syndrome and risk factors for gestational diabetes. Endocrine Connect. 2018;7(7):859–69.

10. Turhan NO, Seckin NC, Aybar F, Inegol I. Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients. Int J Gynaecol Obstet. 2003;81:163–8.

11. Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod. 2003;18:1438–41.

12. Barbour LA, McCurdy CE, Herandez TL, Kivian JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in Normal pregnancy and gestational diabetes. Diab Care. 2007;30(2):511–9.

13. Dunafi A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Rev. 1997;18(6):774–800.

14. Harley A, Witnitzer A. New insights into glucose pathophysiology in gestational diabetes and insulin resistance. Curr Diab Rep. 2010;10(3):242–7.

15. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcome (HAPO) study: associations with neonatal anthropometrics. Diabetes. 2009;58:453–9.